Page last updated: 2024-11-04

carbamylhydrazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Carbamylhydrazine is a white crystalline compound with the formula H2NCONHNH2. It is synthesized by the reaction of hydrazine with urea. Carbamylhydrazine is a potent inhibitor of the enzyme ornithine decarboxylase, which is involved in the biosynthesis of polyamines. It has been investigated as a potential anticancer agent, and its effects have been studied in various cell lines and animal models. Carbamylhydrazine exhibits cytotoxic activity and has been shown to induce apoptosis in cancer cells. Research has also focused on its potential use in treating other conditions, such as parasitic infections and autoimmune diseases. The inhibition of ornithine decarboxylase by carbamylhydrazine may contribute to its anticancer effects by reducing the synthesis of polyamines, which are essential for cell growth and proliferation.'

carbamylhydrazine: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5196
CHEMBL ID903
CHEBI ID28306
MeSH IDM0055304

Synonyms (51)

Synonym
urea, amino-
semikarbazid [czech]
einecs 200-339-6
aminomocovina [czech]
carbamic acid, hydrazide
brn 0506319
hydrazine, carbamoyl-
amino-urea
semikarbazid
carbamylhydrazine
carbazamide
carbamidsaeurehydrazid
CHEBI:28306 ,
aminoharnstoff
lopac-s-2201
NCGC00015934-01
LOPAC0_001096
C02077
aminourea
semicarbazide ,
hydrazinecarboxamide
carbamoylhydrazine
57-56-7
semicarbazide, 6 wt. % (on silica gel)
NCGC00091589-02
NCGC00015934-04
CHEMBL903 ,
bdbm50108606
FT-0655580
A831506
1-azanylurea
aminomocovina
4-03-00-00177 (beilstein handbook reference)
37quc23k2x ,
unii-37quc23k2x
STL163549
BBL012207
CCG-205173
AKOS005716900
NCGC00015934-02
NCGC00015934-03
NCGC00015934-05
DTXSID7043823
carbamic acid hydrazide
isosemicarbazide
Q417535
semicarbazide, 6 wt% on silica gel
SDCCGSBI-0051066.P002
NCGC00015934-06
D95915
SB86096

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Allylamine is toxic to the cardiovascular system causing aortic, valvular and myocardial lesions."( Comparative toxicity of allylamine and acrolein in cultured myocytes and fibroblasts from neonatal rat heart.
Biagini, RE; Breitenstein, M; Krueger, JA; Luken, ME; Toraason, M, 1989
)
0.28
" These results support the concept that AAM is oxidatively deaminated by an SSAO present in vascular cells to generate toxic metabolic by-products capable of causing extensive cellular injury."( Allylamine-induced vascular toxicity in vitro: prevention by semicarbazide-sensitive amine oxidase inhibitors.
Cox, LR; Grossman, SL; Ramos, K, 1988
)
0.27
" Based on estimates of exposure to infants consuming baby foods (with the assumption of SEM levels at the 95th percentile of 20 ng g(-1) in all of the consumed 'ready-to-eat' foods) compared with a no observed adverse effect level (NOAEL) in developmental toxicity studies, the margin of safety is more than 21 000."( Safety assessment and risk-benefit analysis of the use of azodicarbonamide in baby food jar closure technology: putting trace levels of semicarbazide exposure into perspective--a review.
Cheng, E; Goodfellow, GH; Haighton, LA; Lee-Brotherton, VM; Lynch, BS; Musa-Veloso, K; Nestmann, ER, 2005
)
0.33
" Otherwise, it has been described to produce a large number of adverse effects among them cell death mediated mainly by blockage of K(+) channels."( Neuroprotective or neurotoxic effects of 4-aminopyridine mediated by KChIP1 regulation through adjustment of Kv 4.3 potassium channels expression and GABA-mediated transmission in primary hippocampal cells.
Baselga, MJA; Capo, MA; Del Pino, J; Díaz, MJ; Frejo, MT; García, JM; Moyano, P, 2015
)
0.42

Dosage Studied

ExcerptRelevanceReference
" These results suggest that MET is endowed with peculiar hypophagic effects at dosage levels that are not able to affect gross behaviour in mice."( Methylamine and benzylamine induced hypophagia in mice: modulation by semicarbazide-sensitive benzylamine oxidase inhibitors and aODN towards Kv1.1 channels.
Banchelli, G; Galeotti, N; Ghelardini, C; Pirisino, R; Raimondi, L, 2001
)
0.31
" Hypochlorite dosed into milk on an industrial scale, at concentrations extreme for unintentional residues, produced monochloramine, but, without pH adjustment, hypochlorite alone did not generate semicarbazide."( Semicarbazide is non-specific as a marker metabolite to reveal nitrofurazone abuse as it can form under Hofmann conditions.
Bendall, JG, 2009
)
0.35
" Serum estrogen levels were dose-dependently reduced in treated females, whereas dehydrotestosterone serum levels were also decreased but a clear dose-response was not evidenced."( The food contaminant semicarbazide acts as an endocrine disrupter: Evidence from an integrated in vivo/in vitro approach.
Altieri, I; Bolle, P; Catone, T; De Angelis, G; Evandri, MG; Lorenzetti, S; Maranghi, F; Marcoccia, D; Mastrangelo, S; Tassinari, R; Testai, E, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (4)

ClassDescription
monocarboxylic acid amideA carboxamide derived from a monocarboxylic acid.
one-carbon compoundAn organic molecular entity containing a single carbon atom (C1).
ureas
carbohydrazideA hydrazide consisting of hydrazine carrying one or more carboacyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (25)

PathwayProteinsCompounds
L-homocysteine biosynthesis725
spermidine biosynthesis I635
CMP-N-acetylneuraminate biosynthesis II (bacteria)521
methanol and methylamine oxidation to formaldehyde1315
superpathway of C1 compounds oxidation to CO22232
phenylethylamine degradation I220
isethionate degradation010
Spermine Syn413
L-methionine biosynthesis III928
superpathway of L-methionine biosynthesis (by sulfhydrylation)1955
formaldehyde assimilation I (serine pathway)944
L-histidine degradation III213
L-histidine degradation VI120
superpathway of L-cysteine biosynthesis (fungi)628
superpathway of sulfur amino acid biosynthesis (Saccharomyces cerevisiae)1043
superpathway of phenylethylamine degradation939
methylamine degradation I812
superpathway of CMP-sialic acids biosynthesis1460
putrescine degradation IV419
L-arginine degradation VIII (arginine oxidase pathway)325
trans-4-hydroxy-L-proline degradation II643
L-methionine biosynthesis323
cysteine biosynthesis IV (fungi)628
spermine and methylthioadenosine biosynthesis211
spermidine and methylthioadenosine biosynthesis210

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thioredoxin reductaseRattus norvegicus (Norway rat)Potency0.44670.100020.879379.4328AID588453
NFKB1 protein, partialHomo sapiens (human)Potency10.00000.02827.055915.8489AID895; AID928
ThrombopoietinHomo sapiens (human)Potency0.12590.02517.304831.6228AID917; AID918
thyroid stimulating hormone receptorHomo sapiens (human)Potency3.98110.001318.074339.8107AID926; AID938
arylsulfatase AHomo sapiens (human)Potency4.77551.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency23.77810.035520.977089.1251AID504332
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency13.34770.00106.000935.4813AID943; AID944
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Amine oxidase [flavin-containing] AHomo sapiens (human)IC50 (µMol)6.70000.00002.37899.7700AID241583
Amine oxidase [flavin-containing] BHomo sapiens (human)IC50 (µMol)3.35330.00001.89149.5700AID215956; AID241584
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (15)

Processvia Protein(s)Taxonomy
biogenic amine metabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
positive regulation of signal transductionAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
response to xenobiotic stimulusAmine oxidase [flavin-containing] BHomo sapiens (human)
response to toxic substanceAmine oxidase [flavin-containing] BHomo sapiens (human)
response to aluminum ionAmine oxidase [flavin-containing] BHomo sapiens (human)
response to selenium ionAmine oxidase [flavin-containing] BHomo sapiens (human)
negative regulation of serotonin secretionAmine oxidase [flavin-containing] BHomo sapiens (human)
phenylethylamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
substantia nigra developmentAmine oxidase [flavin-containing] BHomo sapiens (human)
response to lipopolysaccharideAmine oxidase [flavin-containing] BHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to ethanolAmine oxidase [flavin-containing] BHomo sapiens (human)
positive regulation of dopamine metabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
hydrogen peroxide biosynthetic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to corticosteroneAmine oxidase [flavin-containing] BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
protein bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
electron transfer activityAmine oxidase [flavin-containing] BHomo sapiens (human)
identical protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] AHomo sapiens (human)
cytosolAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial envelopeAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] BHomo sapiens (human)
dendriteAmine oxidase [flavin-containing] BHomo sapiens (human)
neuronal cell bodyAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (30)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID28658Calculated partition coefficient (clogP) (SlogP)2002Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
Synthesis, biological evaluation, and quantitative structure-activity relationship analysis of new Schiff bases of hydroxysemicarbazide as potential antitumor agents.
AID649113Antinociceptive activity in Swiss mouse assessed inhibition of formaldehyde-induced paw licking at 0.31 mmol/kg, ip administered 30 mins prior to formaldehyde-challenge measured from 15 to 30 mins2012European journal of medicinal chemistry, Apr, Volume: 50Influence of susceptibility to hydrolysis and hydrophobicity of arylsemicarbazones on their anti-nociceptive and anti-inflammatory activities.
AID241583Inhibitory concentration for human liver monoamine oxidase A2004Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24
Fluorinated phenylcyclopropylamines. 2. Effects of aromatic ring substitution and of absolute configuration on inhibition of microbial tyramine oxidase.
AID649117Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 0.31 mmol/kg, ip administered 30 mins prior to carrageenan-challenge measured up to 6 hrs2012European journal of medicinal chemistry, Apr, Volume: 50Influence of susceptibility to hydrolysis and hydrophobicity of arylsemicarbazones on their anti-nociceptive and anti-inflammatory activities.
AID649112Antinociceptive activity in Swiss mouse assessed inhibition of formaldehyde-induced paw licking at 0.31 mmol/kg, ip administered 30 mins prior to formaldehyde-challenge measured up to 5 mins2012European journal of medicinal chemistry, Apr, Volume: 50Influence of susceptibility to hydrolysis and hydrophobicity of arylsemicarbazones on their anti-nociceptive and anti-inflammatory activities.
AID215956Compound was evaluated for inhibition of Microbial tyramine oxidase2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Fluorinated phenylcyclopropylamines. 1. Synthesis and effect of fluorine substitution at the cyclopropane ring on inhibition of microbial tyramine oxidase.
AID96456Activity against lymphocytic murine leukemia cell line L1210 using MTS/PES microculture tetrazolium assay2002Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
Synthesis, biological evaluation, and quantitative structure-activity relationship analysis of new Schiff bases of hydroxysemicarbazide as potential antitumor agents.
AID27913Calculated partition coefficient (clogP)2002Journal of medicinal chemistry, Jan-17, Volume: 45, Issue:2
Synthesis, biological evaluation, and quantitative structure-activity relationship analysis of new Schiff bases of hydroxysemicarbazide as potential antitumor agents.
AID649118Antiinflammatory activity in Wistar rat assessed as inhibition of carrageenan-induced paw edema at 0.62 mmol/kg, ip administered 30 mins prior to carrageenan-challenge measured up to 6 hrs2012European journal of medicinal chemistry, Apr, Volume: 50Influence of susceptibility to hydrolysis and hydrophobicity of arylsemicarbazones on their anti-nociceptive and anti-inflammatory activities.
AID241584Inhibitory concentration for human liver monoamine oxidase B2004Journal of medicinal chemistry, Nov-18, Volume: 47, Issue:24
Fluorinated phenylcyclopropylamines. 2. Effects of aromatic ring substitution and of absolute configuration on inhibition of microbial tyramine oxidase.
AID749465Induction of SSAO-mediated adipogenesis in human bone marrow MSC assessed as adiponectin level at 0.1 to 1 mM after 14 days by ELISA2013Bioorganic & medicinal chemistry letters, Jun-01, Volume: 23, Issue:11
The opposite effect of isotype-selective monoamine oxidase inhibitors on adipogenesis in human bone marrow mesenchymal stem cells.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (287)

TimeframeStudies, This Drug (%)All Drugs %
pre-199060 (20.91)18.7374
1990's64 (22.30)18.2507
2000's83 (28.92)29.6817
2010's67 (23.34)24.3611
2020's13 (4.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 8.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index8.84 (24.57)
Research Supply Index5.70 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (8.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.34%)5.53%
Reviews11 (3.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other286 (95.97%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]